Barclays Thinks Diplomat Pharmacy’s Stock is Going to Recover


In a report released yesterday, Steven Valiquette from Barclays maintained a Buy rating on Diplomat Pharmacy (DPLO), with a price target of $18. The company’s shares closed yesterday at $12.62, close to its 52-week low of $12.52.

According to TipRanks.com, Valiquette is a 3-star analyst with an average return of 3.4% and a 46.3% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and WellCare Health Plans.

Currently, the analyst consensus on Diplomat Pharmacy is a Hold with an average price target of $18.

See today’s analyst top recommended stocks >>

The company has a one-year high of $28.74 and a one-year low of $12.52. Currently, Diplomat Pharmacy has an average volume of 949.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Diplomat Pharmacy, Inc. engages in the provision of pharmacy services. It focuses on improving the lives of patients with complex chronic diseases while delivering solutions for manufacturers, hospitals, payers, and providers.The company was founded by Dale Hagerman and Philip Hagerman in 1975 and is headquartered in Flint, MI.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts